Drugs in ATC Class P02B

Up to Top Level ATC Classes

Up to P - Antiparasitic products, insecticides and repellents

Up to P02 - ANTHELMINTICS

Subclasses in ATC: P02B - ANTITREMATODALS

P02BA - Quinoline derivatives and related substances

P02BX - Other antitrematodal agents

P02B Market Analysis and Financial Projection

The global market for ATC Class P02B Antitrematodals (drugs targeting trematode infections like schistosomiasis) reflects both growth opportunities and challenges stemming from evolving treatment needs, patent dynamics, and emerging resistance patterns. Below is the analysis of key factors shaping this therapeutic class:

---

Market Dynamics

1. Growth Drivers

   • High disease burden: Schistosomiasis affects ~250 million people globally[15], with WHO reports emphasizing 6–7 billion at risk for parasitic infections contributing to P02B drug demand[1].
   • Global health initiatives: WHO-led mass drug administration (MDA) programs for schistosomiasis prioritize praziquantel (P02BA01), with 88.95 million doses administered in 2023[15].
   • R&D innovation: Development of combination therapies (e.g., praziquantel + antimalarials) and reformulations (oral suspensions) to improve compliance in endemic regions[4][17].

2. Market Restraints

   • Drug resistance: Emerging resistance to artemisinin-based therapies in Africa and Asia threatens efficacy, requiring novel mechanisms[1][15].
   • Regulatory hurdles: Strict FDA/EMA guidelines delay approvals for new antitrematodals, with only 1 FDA-approved drug (triclabendazole) since 2019[10][17].
   • Generic competition: Patent expirations (e.g., praziquantel) have reduced prices by 60–80% post-generic entry, pressuring profitability[4][17].

3. Key Trends

   • Repurposing efforts: Patent filings for repurposed drugs (e.g., bosentan for muscular dystrophy[7]) highlight cross-therapeutic R&D strategies.
   • Shift to oral formulations: 70% of pipeline candidates focus on oral delivery to replace injectables, improving accessibility[4].

---

Patent Landscape

Drug	Patent Status	Market Impact
Praziquantel	Expired (generic dominance)	Generics account for 85% of schistosomiasis treatments, priced at $0.20–$0.50/dose[15].
Triclabendazole	FDA-approved in 2019 (Egaten®)	Sole branded drug for fascioliasis; no generics yet, but 3 PCT filings noted[10][18].
Oxamniquine	Limited use due to resistance	No recent patents; largely replaced by praziquantel in clinical practice[9][13].

• Recent Filings:
  • WO/2021/203704 claims bacitracin A (traditionally antimicrobial) for viral proliferation inhibition[2].
  • WO/2023/244738 explores pioglitazone (antidiabetic) for Duchenne muscular dystrophy[7].

---

Competitive Landscape

• Dominant Players: Novartis (Egaten®), Merck KGaA, and Bayer drive 45% of P02B revenue[1][15].
• Emerging Strategies:
  • Public-private partnerships: AdvaCare Pharma collaborates with WHO on low-cost antiparasitics for Africa[1].
  • Geographic expansion: Indian generics manufacturers (Cipla, Sun Pharma) target Latin America and Southeast Asia[4][8].

---

Regional Insights

Region	Market Share	Key Factors
Sub-Saharan Africa	65%	High schistosomiasis prevalence; MDA programs rely on donated praziquantel[15].
Latin America	20%	Fascioliasis outbreaks drive triclabendazole demand[10][15].
Asia-Pacific	10%	Rising healthcare investments and generic production hubs[8][17].

---

Future Outlook

1. R&D Opportunities:

   • Next-gen therapies: CRISPR-based parasite targeting and vaccines in Phase II trials[15].
   • Combination drugs: Dual-action formulations to counter resistance (e.g., praziquantel + ivermectin)[17].

2. Policy Impact:

   • WHO’s 2030 roadmap aims to eliminate schistosomiasis, potentially doubling P02B drug demand[15].

---

The P02B antitrematodal market faces a critical juncture: while generics enhance accessibility, innovation remains vital to address resistance. Strategic patenting of reformulations and partnerships for equitable distribution will shape long-term growth[1][4][15].

References

1. https://www.coherentmarketinsights.com/market-insight/antiparasitic-drugs-market-3782
2. https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647%2FDRUGREPO.24.2.0017
3. https://www.thebusinessresearchcompany.com/report/anthelmintic-drugs-global-market-report
4. https://www.openpr.com/news/3503402/antiparasitic-drugs-market-sales-revenue-analysis-2024-2031
5. https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/nvNsI8S7K9U.pdf
6. https://list.essentialmeds.org/files/trs/KmctuAAMtPBorqeQRged3u44S6eeGKQPvOfhGr65.pdf
7. https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647%2FDRUGREPO.24.1.0012
8. https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report
9. https://en.wikipedia.org/wiki/ATC_code_P02
10. https://go.drugbank.com/drugs/DB12245
11. https://www.pharmacompass.com/chemistry-chemical-name/triclabendazole
12. https://www.csrxp.org/fact-sheet-big-pharmas-patent-abuse-costs-american-patients-taxpayers-and-the-u-s-health-care-system-billions-of-dollars/
13. https://atcddd.fhi.no/atc_ddd_index/?code=P02B&showdescription=yes
14. https://www.bast.de/EN/Traffic_Safety/Subjects/Druid/deliverales-list/downloads/Deliverable_4_1_1.pdf?__blob=publicationFile&v=1
15. https://www.globalgrowthinsights.com/market-reports/drugs-for-schistosomiasis-market-103409
16. https://www.sciencedaily.com/releases/2004/02/040225072931.htm
17. https://www.verifiedmarketresearch.com/product/praziquantel-market/
18. https://www.drugpatentwatch.com/p/atc-class/P02BX